NovoCure NVCR Cash Flow Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| -$136.23M+19.2% | -$168.63M+18.6% | -$207.04M-124% | -$92.53M-58.6% | ||
| $14.65M+30.4% | $11.24M+2.4% | $10.97M+3.3% | $10.62M+3.6% | ||
| $104.83M-34.5% | $160.04M+38.4% | $115.61M+8.1% | $106.96M+12.7% | ||
| -$49.03M-85.9% | -$26.37M+64.0% | -$73.34M— | —— | ||
| $26.65M-37.8% | $42.86M+58.2% | $27.09M+26.9% | $21.36M-11.6% | ||
| $437.28M+412% | -$140.24M-176% | $184.15M+232% | -$139.96M+3.4% | ||
| $99.98M+3.2% | $96.92M— | $0— | $0— | ||
| $560.95M+4,244% | $12.91M+129,030% | $10K-64.3% | $28K+7.7% | ||
| -$451.34M-600% | $90.32M+472% | $15.79M+1.9% | $15.49M-39.7% | ||
| -$62.7M+18.0% | -$76.47M-160% | $126.73M+235% | -$93.78M-156% | ||
| -$75.68M-9.3% | -$69.22M+31.1% | -$100.43M— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does NovoCure's cash flow data come from?
- Every line is extracted from NovoCure's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.